-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 22, Hengrui Medicine issued an announcement stating that it had recently received a notice from the US FDA that Hengrui Medicine’s application for a brief new drug for carmustine for injection declared to the US FDA has been approved.
Carmustine is a nitrosourea compound that can be used as a single drug or combined with other approved chemotherapeutics in palliative care to treat the following aspects:
(1) Brain tumors, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma and metastatic brain tumor;
(2) Combined with prednisone to treat multiple myeloma;
(3) Combined with other lymphomas and approved drugs to treat relapsed or refractory Hodgkin's lymphoma;
(4) Combine other approved drugs to treat relapsed or refractory non-Hodgkin's lymphoma.
Upon inquiry, the global sales of carmustine for injection in 2019 were approximately US$73.